0.43

2.05% -0.009

After Hours: .4367 0.0067 +1.56%

IGC Pharma Inc (IGC)

Overview News Price History Option Chain Discussions Forecast Stock Split

IGC Pharma Inc stock is currently priced at $0.43, with a 24-hour trading volume of 231.89K. It has seen a -2.05% decreased in the last 24 hours and a +7.50% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.4403 pivot point. If it approaches the $0.4117 support level, significant changes may occur.

Previous Close:

$0.439

Open:

$0.4375

24h Volume:

231.89K

Market Cap:

$28.73M

Revenue:

$1.22M

Net Income/Loss:

$-14.15M

P/E Ratio:

-2.0476

EPS:

-0.21

Net Cash Flow:

$-6.55M

1W Performance:

-9.68%

1M Performance:

+7.50%

6M Performance:

+46.76%

1Y Performance:

+29.60%

1D Range:

$0.417

$0.4479

52W Range:

$0.2501

$0.9099

IGC Pharma Inc Stock (IGC) Company Profile

Name

IGC Pharma Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

301-983-0998

Address

4336 Montgomery Avenue, Bethesda, MD

Employee

Twitter

@IGCIR

Next Earnings Date

2024-02-15

Latest SEC Filings

IGC's Discussions on Twitter

IGC Pharma Inc Stock (IGC) Financials Data

IGC Pharma Inc (IGC) Revenue 2024

IGC reported a revenue (TTM) of $1.22 million for the quarter ending December 31, 2023, a +40.09% rise year-over-year.

IGC Pharma Inc (IGC) Net Income 2024

IGC net income (TTM) was -$14.14 million for the quarter ending December 31, 2023, a -1.19% decrease year-over-year.

IGC Pharma Inc (IGC) Cash Flow 2024

IGC recorded a free cash flow (TTM) of -$6.55 million for the quarter ending December 31, 2023, a +12.06% increase year-over-year.

IGC Pharma Inc (IGC) Earnings per Share 2024

IGC earnings per share (TTM) was -$0.26 for the quarter ending December 31, 2023, a 0.00% decline year-over-year.

India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.